ArticleLeukemia2010
Mantle cell lymphoma: transcriptional regulation by microRNAs.
Article in Leukemia, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Clinical outcome prediction by microRNAs in human cancer: a systematic review.Journal of the National Cancer Institute · 2012Pooled it
- Epigenetic dysregulation of B‑cells in autoimmune diseases and lymphomas (Review).International journal of molecular medicine · 2026Review
- Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study.Biomarker research · 2024Article
- MicroRNA Expression Profile in Bone Marrow and Lymph Nodes in B-Cell Lymphomas.International journal of molecular sciences · 2023Article
- Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases.Frontiers in oncology · 2023Review
- The biomarkers of key miRNAs and gene targets associated with extranodal NK/T-cell lymphoma.Open medicine (Warsaw, Poland) · 2022Article
- Non-Coding RNAs in Normal B-Cell Development and in Mantle Cell Lymphoma: From Molecular Mechanism to Biomarker and Therapeutic Agent Potential.International journal of molecular sciences · 2021Review
- Identification of miRNA-34a and miRNA-155 as prognostic markers for mantle cell lymphoma.The Journal of international medical research · 2021Article
- Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies.Oncology letters · 2021Review
- Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma.Leukemia · 2019Article
- Long Non-Coding RNAs Modulate Sjögren's Syndrome Associated Gene Expression and Are Involved in the Pathogenesis of the Disease.Journal of clinical medicine · 2019Article
- MicroRNA profiles in B-cell non-Hodgkin lymphoma.EJIFCC · 2019Review
- Tumor suppressor miR-449a inhibits the development of gastric cancerRSC advances · 2018Article
- Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA.Oncotarget · 2018Review
- MicroRNAs as Biomarkers of B-cell Lymphoma.Biomarker insights · 2018Review
- The miR-106a~363Oncotarget · 2017Article
- MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential.Current genomics · 2015Article
- Review
- miRGate: a curated database of human, mouse and rat miRNA-mRNA targets.Database : the journal of biological databases and curation · 2015Article
- Challenges and opportunities of microRNAs in lymphomas.Molecules (Basel, Switzerland) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma (MCL) pathogenesis is still partially unexplained. We investigate the importance of microRNA (miRNA) expression as an additional feature that influences MCL pathway deregulation and may be useful for predicting patient outcome. Twenty-three MCL samples, eight cell lines and appropriate controls were screened for their miRNAs and gene expression profiles and DNA copy-number changes. MCL patients exhibit a characteristic signature that includes 117 miRNA (false discovery rate <0.05). Combined analysis of miRNAs and the gene expression profile, paired with bioinformatics target prediction (miRBase and TargetScan), revealed a series of genes and pathways potentially targeted by a small number of miRNAs, including essential pathways for lymphoma survival such as CD40, mitogen-activated protein kinase and NF-kappaB. Functional validation in MCL cell lines demonstrated NF-kappaB subunit nuclear translocation to be regulated by the expression of miR-26a. The expression of 12 selected miRNAs was studied by quantitative PCR in an additional series of 54 MCL cases. Univariate analysis identified a single miRNA, miR-20b, whose lack of expression distinguished cases with a survival probability of 56% at 60 months. In summary, using a novel bioinformatics approach, this study identified miRNA changes that contribute to MCL pathogenesis and markers of potential utility in MCL diagnosis and clinical prognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.